Quality of vision and vision-related quality of life after Descemet membrane endothelial keratoplasty: a randomized clinical trial.

"The authors thank Wessel Vermeulen, BSc, and Petra Steijger‐Vermaat, BSc, on behalf of the Cornea Department from ETB‐BISLIFE. Special thanks also go to Liberata Uwantege, Chantal Jumelet‐ van Ast, Maartje Fleuren, Nienke Soeters, PhD, Mark H.L. Willems, BSc, Kim Westra, and Anne Brucker, for their valuable contribution and dedication. Finally, the authors thank the Dutch Cornea Patient Organization (Hoornvlies Patiënten Vereniging) for their support during all stages of the study and Rogier Trompert (http://www.medical-art.nl) for the illustration of the point spread function of the human eye. The Netherlands Association for Health Research and Development (ZonMw), The Hague, The Netherlands; Algemene Nederlandse Vereniging Ter Voorkoming Van Blindheid, Doorn, The Netherlands; Dutch Eyefund, Utrecht, The Netherlands; Dr. F.P. Fischer‐Stichting, Utrecht, The Netherlands; and Landelijke Stichting Blinden en Slechtzienden (LSBS), Ede, The Netherlands. The sponsor or funding organization had no role in the design or conduct of this research. No conflicting relationship exists for any author."

"The authors thank Wessel Vermeulen, BSc, and Petra Steijger‐Vermaat, BSc, on behalf of the Cornea Department from ETB‐BISLIFE. Special thanks also go to Liberata Uwantege, Chantal Jumelet‐ van Ast, Maartje Fleuren, Nienke Soeters, PhD, Mark H.L. Willems, BSc, Kim Westra, and Anne Brucker, for their valuable contribution and dedication. Finally, the authors thank the Dutch Cornea Patient Organization (Hoornvlies Patiënten Vereniging) for their support during all stages of the study and Rogier Trompert (http://www.medical-art.nl) for the illustration of the point spread function of the human eye. The Netherlands Association for Health Research and Development (ZonMw), The Hague, The Netherlands; Algemene Nederlandse Vereniging Ter Voorkoming Van Blindheid, Doorn, The Netherlands; Dutch Eyefund, Utrecht, The Netherlands; Dr. F.P. Fischer‐Stichting, Utrecht, The Netherlands; and Landelijke Stichting Blinden en Slechtzienden (LSBS), Ede, The Netherlands. The sponsor or funding organization had no role in the design or conduct of this research. No conflicting relationship exists for any author."

"The full methods of this study were previously reported in detail (Dunker et al. ). The current study is a prespecified analysis of a RCT comparing secondary clinical outcomes of DMEK and ultrathin DSAEK over 12 months follow‐up. Patients with corneal dysfunction due to FECD were included in six corneal clinics in the Netherlands. The primary outcome measure was BSCVA in logarithm of minimum angle of resolution (logMAR) using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart 12 months after surgery. The study received approval from the institutional review boards of all participating clinics and complied with the tenets of the Declaration of Helsinki. All participants provided written informed consent. Patients were recruited between November 2016 and November 2017. The trial was registered in the US trial register as the DMEK Versus DSAEK Study (www.clinicaltrials.gov, no. NCT02793310, accessed 15 October 2020)."